C4 Therapeutics (CCCC) Operating Income (2019 - 2026)

C4 Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.

• In Q1 2026, Operating Income rose 4.73% year-over-year to -$27.8 million; the TTM figure through Mar 2026 stood at -$113.8 million (up 2.33% YoY), while the FY2025 annual figure was -$115.2 million, up 3.67% from the prior year.
• Operating Income was -$27.8 million for Q1 2026 at C4 Therapeutics, down from -$23.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$21.4 million in Q2 2024 to a low of -$38.3 million in Q4 2022.
• Historically, Operating Income has averaged -$31.2 million across 5 years, with a median of -$31.4 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Operating Income plunged 151.02% in 2022, then surged 42.92% in 2024.
• A 5-year view of Operating Income shows it stood at -$38.3 million in 2022, then advanced by 2.26% to -$37.4 million in 2023, then decreased by 0.75% to -$37.7 million in 2024, then soared by 38.62% to -$23.1 million in 2025, then fell by 20.05% to -$27.8 million in 2026.
• The last three Operating Income figures came in at -$27.8 million (Q1 2026), -$23.1 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.